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Abstract 
 
Hematopoietic Stem Cell Transplantation (HSCT) is a curative therapy for multiple 
malignant and non-malignant blood disorders. Multiple opportunities exist for facilitating 
and improving the accuracy of matching potential donors with patients in need of HSCT. 
The global donor pool does not adequately represent many regions of the world; 
therefore, donor searches would benefit from the haplotype analysis and modeling of 
underserved populations. Utilizing sequence data in matching algorithms also has 
potential to improve HSCT for patients in need. We developed the Gene Feature 
Enumeration (GFE) ecosystem to supplement the current HLA nomenclature by retaining 
all sequence data, hence enhancing matching precision. To improve the global donor 
pool, we performed a haplotype frequency analysis and registry modeling on the Ezer 
Mizion registry in Israel. Combining all these bioinformatics tools provides invaluable 
resources for unrelated donor registries to help serve HSCT patients worldwide. 
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INTRODUCTION	
In 1979 the first unrelated allogeneic hematopoietic stem cell transplantation (HSCT) was 
performed1. Since then advancements in the field of human leukocyte antigen (HLA) 
have helped establish HSCT as a curative therapy for a myriad of malignant and non-
malignant blood-related diseases. Clinical outcomes of HSCT have gradually improved 
with our understanding of the significance of HLA matching between donor and 
recipient.  The best outcomes for HSCT are associated with high-resolution HLA 
matching between donors and recipients2. Matching at HLA-A, -B, -C, -DRB1, and –
DQB1 is the current gold standard when searching for an unrelated donor.  However, 
recent studies have highlighted the potential importance of donor age, CMV status, KIR 
and other HLA loci on HSCT outcomes2,3.  These studies will continue to improve with 
the now routine use of next generation sequencing (NGS) and growing sample sizes4. 
Growing sample sizes and NGS typing will also improve HSCT donor matching 
algorithms by allowing for the reduction of phase and allelic ambiguity.  Matching 
algorithms evaluate phase and allelic ambiguity for scoring the suitability of potential 
donors. If a matching algorithm cannot utilize haplotype frequencies that reflect the 
patient’s ethnicity, then the best-suited donor may not be found due to poorly resolved 
phase ambiguity. For this reason, population-specific haplotype frequencies are critical 
when matching for HSCT. Even with well-described haplotype frequencies, ambiguities 
still arise at the allelic level that can impact the outcomes of HSCT. Before a transplant, 
high-resolution HLA typing is routinely done on the recipient and any prospective donors 
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to resolve these ambiguities. However, allelic ambiguities still exist that are not 
considered during the matching process. Matching is currently done at the second field 
(protein level) of the HLA nomenclature; therefore, ambiguities to the third and fourth 
field still exist between the donor and recipient5.  Matching to the fourth field would 
utilize more detailed linkage information that would allow for more precise match 
predictions. With current NGS typing technologies, we could go beyond that and 
determine the best match between donor and recipient at the sequence level.  Sequence 
level analysis of patients HLA data could also be extremely informative for HLA disease 
association studies6. Unfortunately, these types of studies cannot be done with the current 
HLA nomenclature, because it does not retain all sequence variations.7 The current HLA 
nomenclature will need to be extended to resolve allelic ambiguity any further.  Phase 
ambiguity present in matching algorithms could be reduced with the development of 
haplotype frequencies and donor modeling for poorly represented regions of the world. 
Our aim was to improve the current capabilities of resolving phase and allelic ambiguity 
for HSCT. We developed the gene feature enumeration (GFE) ecosystem as a way of 
extending the current nomenclature, and therefore as a way to further resolve any allelic 
ambiguity. We developed haplotype frequencies and performed modeling for the Ezer 
Mizion Bone Marrow Donor Registry in Israel. These results will better define the HLA 
haplotype distributions of the Middle East, and will, therefore, help resolve phase 
ambiguity for patients with Middle Eastern ancestry. Together, the GFE Ecosystem and 
Ezer Mizion analysis provide invaluable resources for unrelated donor registries to help 
better serve HSCT patients worldwide. 
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Chapter 1: The Gene Feature Enumeration Ecosystem 
SYNOPSIS 
A publicly available service for assigning HLA allele names to consensus sequences 
would be a valuable community resource. It would allow researchers the ability to  
Our aim was to use existing technologies to develop a publicly available, graph-based 
HLA allele calling service. Gene feature enumeration (GFE) notation has been developed 
as a way of describing sequence variation outside of current HLA nomenclature. We 
generated GFE notation for every sequence in the IPD-IMGT/HLA Database, and loaded 
the results into a neo4j graph database (neo4j.b12x.org), which includes HLA, GFE and 
sequence feature nodes. We developed an allele-calling tool (ACT) that leverages this 
graph to return an HLA allele call and GFE notation from submitted consensus sequence. 
ACT uses the GFE service (gfe.b12x.org) to convert the consensus sequences to GFE 
notation, and then searches the graph database for HLA alleles that share the most 
features with the generated GFE. A RESTful service interface makes ACT easy to use 
and allows for cross-platform compatibility (act.b12x.org). We used 30,000 Be the 
Match® donors typed at high resolution and with consensus sequences available for 
HLA-A, B, and C to test ACT.  We compared the HLA calls ACT produced to the allele 
names reported by the typing labs. Comparisons were made with and without mapping 
alleles to their G group equivalent. When mapping alleles to their respective G group 
equivalent, the reported HLA typing for all 30,000 donors matched the ACT typing to the 
2nd field with no ambiguity. Without mapping alleles to their G groups, the number of 
exact matches to the 4th field at HLA-A, B and C was 17,142 (57%), 16,540 (55%) and 
  4 
10,024 (33%), respectively. Using G groups, ambiguity at the 4th field was reduced 
substantially; the number of exact matches increased to 29,914 (99.7%), 29,733 (99.1%) 
and 29,985 (99.9%) for HLA-A, B, and C, respectively. In 75 instances, ACT called 
alleles at a higher resolution than reported by the typing lab. HLA class I allele names 
can be accurately called from consensus sequences using our GFE-based ACT. This 
service will allow anyone to easily convert HLA class I consensus sequences into the 
corresponding GFE notation and HLA allele name. Class II HLA and KIR are already 
represented in the graph, and we plan to extend ACT functions to these loci. 
INTRODUCTION  
Innovations in human leucocyte antigen (HLA) genotyping technologies have caused a 
dramatic expansion in the number of known HLA alleles several times over the last 
decade7.  HLA is the most polymorphic region of the human genome, making the 
accurate typing of HLA genes complicated2.  Only recently have sequencing companies 
developed typing platforms and kits that are capable of sequencing HLA with high 
accuracy.  These improvements in HLA sequencing technologies create challenges for 
the current HLA nomenclature8. Polymorphisms present in features of a gene are not 
always captured accurately with the current nomenclature5. Potentially useful sequence 
data is lost because of the divide between sequencing technology and nomenclature. 
Bridging this divide could extend the precision of disease association studies and 
potentially improve outcomes for hematopoietic stem cell transplantation (HSCT). The 
gene feature enumeration (GFE) notation was established to supplement the current HLA 
nomenclature by retaining all the lost sequence information9. The feature service 
  5 
(feature.nmdp-bioinformatics.org) was developed as a way of storing and retrieving the 
accession numbers in a GFE notation. Programmatically generating GFE notation with 
consensus sequences became possible after the creation of the GFE service 
(gfe.b12x.org).  These services made GFE accessible to the community and created an 
active discussion around the future potential of such technologies. From these 
discussions, the concept of a GFE based, publicly available, open sourced system for 
extending the IPD-IMGT/HLA database and HLA nomenclature emerged. Establishing a 
link between the GFE notation and the current IPD-IMGT/HLA database was an essential 
part of the GFE Ecosystem. Our aim was to complete the GFE Ecosystem by developing 
a publicly available GFE database (GFE DB) and a graph-based HLA allele-calling 
service.  
METHODS 
Feature Service 
To make the GFE notation useful there needed to be a database for storing and retrieving 
the accession numbers. The feature service provides this by offering a RESTful interface 
for generating and retrieving the accession numbers (Figure 1A).  A user can POST a 
Sequence Ontology (OS) term (ex. Exon, Intron, etc.), the term rank, the gene name and 
the sequence and receive the corresponding accession number. Users can also POST a SO 
term, rank, gene name and accession number and receive the corresponding sequence. 
The accession numbers are created by incrementing at each newly observed sequence for 
the provided gene name, OS term and rank. Therefore, the accession number for the first 
sequence submitted for each gene, SO term, and rank will always be one.  To make sure 
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the accession numbers are consistent throughout the community there is only one feature 
service publicly available.  The feature service is intended as a storage and retrieval 
service only and has no real computational capabilities. Joining the feature accession 
numbers associated with a gene sequence creates a GFE notation, but the feature service 
does not directly generate GFE.  The accession numbers are generated by first extracting 
the gene features from the sequence. 
Annotation Pipeline 
The annotation pipeline offers a way of extracting the features from a given sequence 
using Clustal Omega (Figure 1B)10. The annotation pipeline consumes sequence data 
from FASTA files and produces text files containing the sequences associated with each 
feature in the sequence.  We generated reference alignment files for each HLA and KIR 
locus that allowed for the quick identification of the coordinates of gene features in a 
sequence. A phylogenetic analysis was done to determine the best sequences to use in the 
reference alignments for each locus. Comparing the results to the sequence annotations 
on IPD-IMGT/HLA validated the annotation pipeline. The annotations for class I loci 
(HLA-A, B, and C) are very accurate due to highly conserved regions but are less 
accurate for class II loci (HLA-DRB1, DQA1, DQB1, DPA1 and DPB1). The annotation 
pipeline is publicly available on Github (github.com/nmdp-bioinformatics/HSA), but is 
not available as a service or easily built locally. 
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Figure 1. The GFE Ecosystem. A) The feature service accepts sequence features and returns the 
corresponding accession number. B) The annotation pipeline is used to extract sequences of 
features for submitting to the feature service. C) The GFE Service uses the annotation pipeline to 
align sequences and then submits them to the feature service. The corresponding accession 
numbers are combined to create a GFE notation. D) The GFE DB contains all of the sequence 
data in IPD-IMGT/HLA and also persists the corresponding GFE notation. E) The ACT Service 
creates GFE notation from consensus sequences using the GFE service and then searches the GFE 
DB for the corresponding HLA alleles. 
GFE Service 
At the fourth Immunogenetics Data Standards Hackathon (DaSH) in Vienna, Austria we 
developed the GFE service so that anyone could generate GFE notation from sequence 
data (Figure 1C).  This service has played an important role in the adoption GFE notation 
by allowing anyone to produce GFE notation from a RESTful API easily. Before the 
GFE service was available all GFE notation was created manually and could not be done 
for large numbers of sequences. The GFE service was developed with the same RESTful 
principals as the feature service, allowing anyone on any platform to utilize it. Users can 
post HLA and KIR sequence data to the service and receive the GFE notation in return. 
Within the GFE Service the annotation pipeline is being run on the submitted sequences 
to extract the features. The features are passed to the feature service to attain the 
A) 
B) 
C) E) D) 
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corresponding accession numbers. The returned accession numbers are then placed in 
their genomic order and joined to create the GFE notation.  Users can get back the full 
sequence associated with a GFE by submitting the GFE to the ‘seq’ API.  Like the feature 
service, it is also publicly available on Github (github.com/nmdp-bioinformatics/service-
gfe-submission) and Dockerhub (hub.docker.com/r/nmdpbioinformatics/service-gfe-
submission), making it exceptionally easy to deploy locally.  
GFE DB 
The sequences in IPD-IMGT/HLA are connected in many different ways, and IPD-
IMGT/HLA does not persist these connections. These connections, such as shared exons, 
could be represented in a graph database and efficiently queried. This type of 
functionality would be a tremendous improvement from what the IPD-IMGT/HLA 
currently offers. Establishing a link between the GFE notation and the HLA allele names 
on IPD-IMGT/HLA was a crucial reason for building the GFE DB.  
We first established a database schema that would capture as many connections as 
possible while still retaining the original information. 
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Figure 2. The database schema used for modeling the GFE DB. 
We developed the schema for the GFE DB (Figure 2) by first creating the nodes 
we wanted represented in the graph: IMGT, GFE, FEATURE, SEQUENCE, and 
GROUP.  The IMGT nodes represent the HLA allele names from IPD and do not have 
any sequence information contained in the node properties. The IPD-IMGT/HLA 
database version, allele name, and locus are simply the dbversion, name, and locus 
properties in the node. The IMGT nodes are connected to GFE, FEATURE and 
SEQUENCE nodes. Like the IMGT nodes, the GFE nodes only have dbversion, name 
and locus as properties and are also connected with the FEATURE and SEQUENCE 
nodes. Both the IMGT and GFE nodes are connected to the FEATURE and SEQUENCE 
nodes by the HAS_FEATURE relationship.  This relationship has two critical properties: 
status and accession. The accession numbers returned by the feature service are stored as 
the accession property in the relationship. The status indicates whether the feature was 
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generated from taking the exact coordinates from IPD-IMGT/HLA (Expected) or if the 
feature was generated using the GFE service (Observed). 
For each HLA sequence in IPD-IMGT/HLA an observed and expected 
relationship exists. The HAS_GFE relationship also has the status property but does not 
contain any information on relating to the sequence. The SEQUENCE nodes contain the 
full sequence taken from IPD-IMGT/HLA and therefore only have expected 
HAS_FEATURE relationships. The FEATURE nodes have the same properties as the 
SEQUENCE nodes, which are: name, sequence, rank, length, and nuc.  In the 
SEQUENCE node, the name and rank are “Sequence” and 0. However, in the FEATURE 
nodes they represent the name of the feature (exon, intron, etc.) and the rank of that 
feature.  The “nuc” property is an array of the sequence, which allows for querying 
specific positions in a sequence.  
Broader queries can be made using the GROUP nodes, which are the only nodes 
without any inward pointing edges. The GROUP nodes represent different groupings of 
the HLA alleles, such as G_GROUP and P_GROUPS, which are defined on IPD-
IMGT/HLA. HLA alleles that have the same nucleotide sequence in the antigen 
recognition site are considered to be in the same G_GROUP. Similarly, alleles that have 
the same protein sequence in the antigen recognition site are in the same P_GROUP. The 
group nodes contain the type of node being represented, the name of the group (ex. HLA-
A*01:01:01G) and the IMGT/HLA database version associated with that group. Each 
group node points to the alleles that are found within that group.   
  11 
With the schema established, we worked on producing the data needed for 
populating the graph. We produced the raw data files needed for populating the graph in 
three steps: generating the expected, generating the observed and finally formatting the 
results into bulk load files.  We used the HLA.xml file for the IPD-IMGT/HLA version 
3.26.0 to create both the expected and observed results. Every HLA allele in IPD-
IMGT/HLA is represented by an element within the XML file. Within the allele element 
is a sequence element, which contains the full sequence associated with the allele. The 
sequence element also contains tags for each specific feature present in the sequence and 
the corresponding coordinates for those features within the sequence. We produced the 
expected sequence features by using these coordinates and the full sequence. For every 
allele in IMGT/HLA, we extracted the sequence features and then passed them to the 
feature service to get the expected accession numbers. We used these expected accession 
numbers to create the expected GFE notation for each HLA allele in IMGT/HLA. The 
produced expected file contained the HLA allele name, the GFE notation, the full 
sequence, and a list of the features with the corresponding sequence and accession 
number for each HLA allele.  The observed file was formatted the same way, however, 
instead of generating the GFE notation and features from the known coordinates we used 
the GFE service.  
The GFE service can convert a consensus sequence into GFE notation in about 5 
to 10 seconds, depending on the locus and the length of the sequence. When dealing with 
a handful of sequences the runtime is not an issue, but it can be a substantial barrier when 
dealing with thousands of sequences. To expedite the processing of all the IPD-
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IMGT/HLA sequences we stood up several Amazon Web Service (AWS) instances and 
used docker to run the GFE service locally on each machine. We broke up the HLA.xml 
file containing the IPD-IMGT/HLA database into three equal parts and allocated one part 
per machine. Each sequence was run through the GFE service in parallel using a nextflow 
script. Nextflow allows for the GFE client scripts to be run in parallel and efficiently 
utilizes the available CPU11. Up to 40 sequences ran in parallel on each machine, 
allowing for roughly 120 sequences to be run in parallel across all machines.  
Building a neo4j graph database is straightforward when using the neo4j-import 
tool. Only four arguments are needed for building a neo4j graph database with the import 
tool: id-type, into, nodes, and relationships. The “--into” argument specifies the location 
of the graph database and needs to match the “dbms.directories.data” variable in the 
neo4j.conf file. The “--id-type” argument will either be INTEGER or CHARACTER 
depending on the type of IDs used for the nodes and relationships. The “--nodes" and “--
relationships" arguments specify CSV files that contain the nodes and the relationships in 
the graph. For the GFE DB, we created two node files and three relationship files. We 
generated these files from the expected and observed results using a Perl script. Running 
the import command with these files populates a Neo4j graph database and starts a server 
with a web interface available on port 7474. The code for building the graph can be found 
on Github (github.com/nmdp-bioinformatics/gfe-db) and a docker image containing the 
graph is available on Dockerhub (hub.docker.com/r/nmdpbioinformatics/gfe-db).  
  13 
ACT Service 
Designing the API for the ACT Service was done using the Swagger editor (swagger.io). 
We designed five APIs for utilizing the GFE DB: hla, gfe, ars, sequence, and act. We 
defined the parameters and responses for each API call in the YAML swagger 
specification. We generated a Python Flask server using the Swagger specification file 
and the Swagger code generation tool. The generated server code was modified to import 
python modules that contained the main functionality for each API. The function of each 
API was made possible through cypher queries that search the GFE DB.  
The “/gfe” API allows users to find every GFE notation associated with a 
particular HLA allele.  Similarly, the “/hla” API allows users to find every HLA allele 
associated with a particular GFE notation. The ARS group associated with a given GFE 
notation or HLA allele can be determined using the “/ars” API.  Getting the sequence 
associated with a GFE notation, HLA allele or feature for an HLA allele can be done 
using the “/sequence” API.  The main API exposed by the ACT service is the “/act” API, 
which also offers the most complex functionality. The ACT API generates GFE notation 
from consensus sequences and makes HLA allele calls to the fourth field. Users provide 
an HLA locus and consensus sequence and receive an array of HLA alleles associated 
with that consensus sequence as well as the GFE notation.  
The functionality behind the “/act” API is broken up into five parts, each using 
separate cypher queries for getting data from the GFE DB. First, the service checks 
whether the provided sequence exists in the GFE DB. If the sequence exists, then the 
service simply returns the HLA and GFE associated with that sequence in the graph. If 
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the sequence does not exist in the graph, then it is converted to GFE notation by making a 
call to the GFE service. The service extracts the accession numbers associated with exons 
two and three from the generated GFE. The typing of these exons is required for every 
HLA class I sequence submitted to IPD-IMGT/HLA.  Classification into the “G” groups 
is also done at these exons, making them informative for producing HLA allele calls. The 
accession numbers associated with these exons are then used to search the graph for all 
GFE that share them. The service returns a list of GFE notations that share the same 
exons two and three as the previously created GFE.  From this list, the GFE notations that 
share the most accession numbers with the generated GFE are taken. The remaining GFE 
will have the most features identical in sequence to the posted consensus sequence. An 
HLA allele call is made by finding the alleles associated with these returned GFE. The 
service will return a JSON object with a “gfe” element that contains the generated GFE, a 
version element that has the ACT version and an “hla” element that contains an array of 
HLA alleles. If the service fails to make an allele can then the “hla” element will be 
empty. 
Validation 
Extensive validation is essential for proving the utility of any new tool.  
Comparing expected to observed results was the validation approach used for both the 
GFE DB and the ACT service. We compared the number of alleles successfully loaded in 
the GFE DB to the expected number of alleles at each locus. We also compared the raw 
data from IPD-IMGT/HLA to nodes with expected relationships.  
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We compared the accession numbers of the expected relationships to the observed for 
each feature type and locus. Similarly, we compared the expected GFE notation to the 
observed at each locus. To identify how often the expected and observed sequences 
differed by three base pairs, we wrote cypher queries to compare the beginning and ends 
of sequences.  
 The accuracy of the ACT service was evaluated using 30,000 Be the Match® 
donors typed at HLA-A, B, and C with consensus sequences available. We stood up three 
AWS c4.large instances and used Docker to deploy both the GFE and ACT services 
locally on each machine. A python tool that utilizes the ACT service client was run in 
parallel on each machine using a nextflow script. We compared the allele calls produced 
by the ACT service to the allele calls reported by Histogenetics for each donor. We made 
comparisons with at the second, third and fourth field with and without alleles reduced to 
their ARS equivalent.  
RESULTS 
GFE DB 
In five hours all of the IPD-IMGT/HLA sequences finished being processed by the GFE 
service. The number of HLA alleles persisted in the GFE DB matches the number of 
HLA alleles available on IPD-IMGT/HLA. The nodes with expected relationships 
correctly represent all of the sequence data available on IPD-IMGT/HLA. Table 1 shows 
how many alleles successfully ran through the GFE service for each locus. As expected, a 
significant portion of sequences for class II could not be processed. However, every 
sequence for class I was successfully processed by the GFE service.  HLA-DPB1 
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performed the worst, with only 26 sequences being successfully processed by the GFE 
service. We expected this due to variability among HLA-DPB1 sequences that the 
reference alignment file could not appropriately capture. The number of times the 
observed GFE matches the expected for each sequence in IPD-IMGT/HLA is depicted in 
Table 2. HLA-A performed the best with only 10.5% of the observed GFE matching the 
expected. None of the observed class II GFE matched the expected. Slight variations in 
the sequences would cause the expected to mismatch with the observed; therefore these 
numbers were not expected to be high. When comparing the observed to the expected at 
the level of the features, the accuracy was much higher (Appendix A: Table 7). On 
average the expected sequence matched the observed 71% of the time at the exons for 
class I and 99% of the time at the introns. The expected 5’ UTR sequence matched the 
observed only 10% of the time for class I, which impacted the majority of the mismatches 
between the expected and observed GFE. Some of the mismatches at the feature level are 
explained by three base pairs being removed or added at the beginning or end of an exon. 
In these cases, the annotation pipeline incorrectly identifies the exon boundaries and 
nucleotides are added to or removed from an adjacent exon. These are observed over 200 
times at exon three for each class I locus and is most commonly observed at HLA-B 
(Appendix A: Table 8).  
 
 
 
 
  
  17 
Locus	 Persisted	Sequences	 Sequences	in	IPD-IMGT/HLA	
HLA-A	 3657	 3657		
HLA-B	 4459	 4459	
HLA-C	 3296	 3296	
HLA-DPB1	 26	 716	
HLA-DQB1	 116	 978	
HLA-DRB1	 95	 1972	
Table 1. The number of HLA sequences that are persisted in the GFE DB. 
 
Locus	 Matched	GFE	 Percent	Match	
HLA-A	 381	 10.46%	
HLA-C	 96	 2.16%	
HLA-B	 319	 9.70%	
HLA-DRB1	 0	 0.00%	
HLA-DQB1	 0	 0.00%	
HLA-DPB1	 0	 0.00%	
Table 2. The number of times the expected GFE notation matched the observed. 
ACT Service 
Using nextflow and three AWS instances we ran all 30,000 donors through the ACT 
service in 10 hours.  When mapping alleles to their G group equivalent, the reported HLA 
typing for all 30,000 donors matched the ACT typing to the 2nd field with no ambiguity. 
Without mapping alleles to their G groups, the number of exact matches to the 4th field at 
HLA-A, B, and C was 17,142 (57%), 16,540 (55%) and 10,024 (33%), respectively. 
Using G groups, ambiguity at the 4th field was reduced substantially; the number of exact 
matches increased to 29,914 (99.7%), 29,733 (99.1%) and 29,985 (99.9%) for HLA-A, B, 
and C, respectively. In 89 instances, ACT called alleles at a higher resolution than 
reported by the typing lab. 
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DISCUSSION	
We have shown that the GFE notation offers solutions to many of the current issues 
facing the HLA nomenclature; therefore, it would be a useful addition to the next version 
of the nomenclature. Researchers interested in studying sequence variation not captured 
by the current naming convention could utilize the GFE Ecosystem for generating and 
analyzing GFE notation. The GFE DB offers researchers the ability to query the sequence 
data in IPD-IMGT/HLA in ways that are not currently possible. Sequence data can now 
be easily retrieved for alleles or features by simple queries. With the IPD-IMGT/HLA 
database, these operations would have to be done manually and could be time-consuming 
tasks. More flexibility is also offered with the GFE DB interface, which allows users to 
interact with and visualize the data. For developers, the Docker image of the GFE DB 
offers the ability to quickly stand up a version locally. Being able to run the GFE DB 
locally makes it more likely to be adopted by the broader immunogenetics community.  
The GFE DB also offers valuable insight into the current limitations of the annotation 
pipeline.  
The annotation pipeline is not currently capable of reliably processing class II 
consensus sequences. This limitation was known before the creation of the GFB DB, but 
it was not clear which alleles would fail. The next iteration of the annotation pipeline will 
include more reference alignments that better represent the sequences that failed to be 
processed. Adding a step to the annotation pipeline to determine what reference 
alignment to use could address this issue as well. Partial class II and KIR sequences may 
still fail to be processed with this approach; therefore, we will need to apply different 
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methods for annotating sequences. One option is to use a Hidden Markov Model (HMM) 
for identifying the gene features in a sequence. Numerous research groups have validated 
the accuracy of using HMMs to identify gene features12. Taking this approach would be 
useful for partial sequence data where the exons are separated by large unreported 
introns. Alignment algorithms often fail to align these sequences because of the large 
gaps between the exons. These gaps would not effect the prediction of the gene features 
when using a HMM. We have already started the development of a HMM that is 
specifically built for HLA and will be included in the next release of the annotation 
pipeline. 
The coordinates of the gene features returned by the annotation pipeline are 
slightly off for the vast majority of the sequences in IPD-IMGT/HLA (Table 2).  While 
this inaccuracy highlighted issues with the annotation pipeline, it did not affect the 
accuracy of the allele-calling tool. These slight differences actually help improve the 
accuracy of the ACT, by providing the service with more variation to compare with. 
A typing lab can produce numerous unique sequences that all represent the same HLA 
allele, and each would represent a different GFE notation. Every variation captured in the 
GFE DB for an allele makes the ACT service more accurate at calling that specific allele. 
Therefore, without both the expected and observed GFE results persisted, the ACT 
service wouldn’t have been as accurate. In next version of the ACT service and GFE DB, 
there will be an option for users to persist submitted results to the database. Being able to 
store sequences that identify with a specific allele would improve the accuracy of the 
ACT and allow researchers the ability to curate their data. 
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The technologies adopted by the GFE Ecosystem will allow for seamless 
integration into existing data pipelines. The RESTful framework separates platform and 
language giving developers the freedom to program clients in any language they desire. 
With Docker, developers can package entire web applications into isolated containers that 
can be run on any machine. Anyone who has Docker installed can build the entire GFE 
Ecosystem locally in minutes by pulling from Dockerhub with one docker-compose 
command. Unlike Dockerhub, Github contains everything that is needed for anyone to 
contribute to the development process of the GFE Ecosystem.  Researchers in the field 
have already shown interest by providing feedback and by following the repositories on 
Github. Continued community engagement in the development process will ensure the 
adoption and sustainability. 
The most active engagement has been around the ACT service and how it can be 
utilized in current pipelines. HLA class I allele names can be accurately called from 
consensus sequences using our GFE-based ACT. Having no ambiguity at the second field 
after reducing to the ARS equivalents is a significant feat for an allele-calling tool and 
could be a useful tool for research groups. None of the publicly available tools for 
making HLA allele calls work well with consensus sequences and do not utilize the same 
technologies as the GFE Ecosystem. The ACT service is the only available allele-calling 
tool that implements a RESTful framework, which allows it to be utilized with simple 
HTTP requests. No publicly available tool exists for making Class II and KIR allele calls 
from consensus sequences. Extending the capabilities of the ACT service to these loci 
will make it substantially more useful. The next release of the ACT service will include 
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the ability to make class II and KIR allele calls using the updated version of the 
annotation pipeline. 
Taken together, all of these services make up the GFE Ecosystem: an open 
sourced, community driven system for extending the IPD-IMGT/HLA database and 
nomenclature. The GFE Ecosystem offers a solution to the problems facing the current 
nomenclature and will allow everyone to partake in the process of creating HLA allele 
names. Sequence data will no longer be lost in allele names and waiting for IPD-
IMGT/HLA to provide a name for a new sequence will no longer be an issue. Most 
importantly, this system opens up the development process and tools to the whole 
community. Hospitals and research labs paying for tools whose functions are done by the 
GFE Ecosystem could save money and gain the advantages of using GFE.  
Unforeseen research opportunities could also be found from utilizing the data exposed by 
the GFE DB. All of these benefits demonstrate potential for the GFE Ecosystem to have a 
dramatic impact on the field of immunogenetics. The current system will inevitably adopt 
some change, with or without GFE. With the GFE Ecosystem the immunogenetics 
community will be better prepared for impending flood of sequencing data. This will 
allow for cutting edge research to be done and life saving discoveries to be made. 
 
  
  22 
Chapter 2: High-resolution HLA A~B~DRB1 haplotype 
frequencies from the Ezer Mizion Bone Marrow Donor 
Registry in Israel 
 
Sigal Manoraǂ, Michael Halaganbǂ, Nira Shrikia, Isaac Yaniva,c,d, Bracha Zissera,  Martin 
Maiersb, Abeer Madboulyb, Jerry Steinc,d  
 
a Ezer Mizion Bone Marrow Donor Registry,  Petach Tikva, Israel 
b Bioinformatics Research, National Marrow Donor Program, Minneapolis, MN, USA 
c Bone Marrow Transplant Unit, Schneider Children's Medical Center of Israel, Petach 
Tikva, Israel 
d Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 
 
ǂ These authors contributed equally to this work 
 
I performed every analysis and generated the figures, tables and supplementary tables for 
this study. I wrote the methods and the first part of the results section. I also contributed 
to the revising of the introduction and discussion sections.  
 
DOI: https://doi.org/10.1016/j.humimm.2016.09.004 
SYNOPSIS 
We have investigated HLA population alleles and haplotype frequencies for the 
ethnicities that comprise the contemporary population of Israel, using a large data set 
from the Ezer Mizion Bone Barrow Donor Registry. We genotyped 275,699 individuals 
at the HLA-A, -B and -DRB1 loci using HLA genotyping methods. HLA A~B~DRB1 
haplotype frequencies were estimated from 19 sub-ethnic Jewish populations and other 
non-Jewish minorities using the maximum likelihood model, which accommodates 
typing ambiguities. We present overall and sub-ethnicity specific HLA diversity results 
of the registry, which will help guide a data-driven strategy for future registry expansion. 
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INTRODUCTION 
Israel is home to the entire genetic spectrum of the Jewish Diaspora as well as for non-
Jewish minorities, leading to marked ethnic diversity in a country of only eight million 
individuals. Before the founding of the modern state of Israel (1948), the Jewish Diaspora 
consisted of separate Jewish communities in Europe, North Africa, and Asia. Ancient 
communities of Jewish exiles formed in Iran and Iraq from the 7th to the 5th centuries 
BCE. From the 1st century BCE onward, Jewish communities spread westward through 
the north and south coasts of the Mediterranean basin, throughout the Levant and inland 
into the European continent. Subsequently, Jewish populations expanded in central and 
eastern Europe, along the North African coast and in the southern Arabian peninsula. 
Jews migrated eastwards from the Persian Empire and reached as far as India and China. 
Toward the late 19th century through the 20th century, there was significant immigration 
of Jews from Europe to North and South America. Admixtures of Jewish migrants with 
indigenous host populations led to increasing genetic diversity between individual 
Diaspora communities, while cultural and religious forces maintained coherence of the 
Jewish people13–15. During the last 100 years, increasing immigration to Israel, together 
with the growth of Muslim and Druze populations within the boundaries of the State have 
resulted in a panoply of subethnicities that make up the patchwork of modern Israeli 
society. As second and third generation Israelis start marrying outside of their ancestral 
subethnicities, an additional layer of allelic diversity has been introduced into the HLA 
landscape in Israel, leading to intergenerational immunogenetic differences within the 
Israeli population16. In the last decades, the successful use of highly matched unrelated 
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volunteer donors for hematopoietic stem cell transplantation (HSCT) has stimulated the 
development of many national volunteer unrelated donor stem cell registries. This paper 
outlines analyses of HLA population haplotype frequencies in a large stem cell donor 
registry to characterize the genetic population profile of the contemporary Israeli 
population. In addition to the large extent of the population size analyzed, the high-
resolution HLA profile presented in this study improves on data obtained in previous 
studies14,17–20. This analysis is the first phase of a project that seeks to guide strategic 
planning for donor recruitment and expansion of the Ezer Mizion Bone Marrow Donor 
Registry (EM BMDR) in Israel.  
METHODS 
Study population  
We examined all 754,135 unrelated volunteer donors registered in EM BMDR from its 
inception through June 2014 to gauge HLA haplotype diversity within the Israeli 
population. All subjects provided informed consent for registration at recruitment and 
self-reported their parents’ country of origin, permitting us to assign subethnicities. Each 
sub-ethnic population included only individuals who self-reported the same sub-ethnic 
population for both parents; multi- or mixed-ethnicity donors were excluded from this 
analysis. The study was approved by the Ethics Committee of Rabin Medical Center, and 
was conducted in accordance with the 2014 Ministry of Health (Israel) Guideline for 
Clinical Trials in Human Subjects. 
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Table 3. A list of all 19 analyzed Ezer Mizion populations and sample counts. 
Ezer Mizion populations Sample counts 
Arab 12,300 
Argentinaa 4,307 
Ashkenazi 4,625 
Bukhara 2,317 
Druze 5,914 
Ethiopia 5,928 
Georgia 4,471 
Iran 8,153 
Iraq 13,270 
Israel 69,716 
Kavkaz 2,840 
Libya 3,739 
Morocco 36,718 
Poland 13,871 
SEEb 11,179 
Tunisia 9,070 
USAa 6,058 
USSRc 45,681 
Yemen 15,542 
Total 275,699 
a Argentina and USA population are derived from emigrants of European Jews 
b SEE include Romania, Bulgaria, Moldova, Greece, Yugoslavia, Albania, Serbia, Transylvania and Cyprus 
c USSR include Russia, Ukraine, Belarus, Lithuania, Latvia and East Europe 
HLA genotyping  
HLA typing analyses evolved during the building of the EM BMDR roster, starting with 
serologic determinations and evolving to DNA- based testing at low, intermediate, and 
allele resolution (SSO-, SSP-, or SBT based). Only data genotyped by DNA-methods was 
used in this analysis. The initial dataset included 67 sub-ethnicities, with an average 
sample size of 5200 (2–79,066) per population. However, only 19 populations, 
containing a total of 275,699 donors, were large enough for analysis, based on a 
minimum sample size per of >200 high-resolution typed samples at HLA-A, -B and -
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DRB1 loci per sub-ethnicity (Table 3). It should be noted that Argentina and USA 
population are derived from emigrants of European Jews; SEE sub-ethnic population 
include Jews from Romania, Bulgaria, Moldova, Greece, Yugoslavia, Albania, Serbia, 
Transylvania and Cyprus; USSR sub-ethnic population include Jews from Russia, 
Ukraine, Belarus, Lithuania, Latvia and East Europe.  
HLA allele and haplotypes frequency analysis  
Three-locus haplotype frequencies (A~B~DRB1) were estimated for each of the 19 
populations, resolving phase and allelic ambiguity using the expectation–maximization 
(EM) algorithm21,22. The applied EM algorithm was designed to handle mixed resolution 
data23,24. Allele frequencies were calculated by summing across the haplotype 
frequencies. Deviations from Hardy– Weinberg equilibrium (HWE) were assessed at the 
allele-family level (first nomenclature field) using a chi-squared test as implemented in 
the software PyPop25.  
Clustering analysis  
HLA haplotype frequency visualizations on the study populations were created using the 
CLUTO software26 by clustering the top 100 haplotypes (rows) in the 19 studied 
populations, and separating them into eight clusters of haplotypes based on haplotype 
similarity across populations (columns). It should be noted that since CLUTO examines 
only the top 100 haplotypes in each sub-ethnicity, this analysis may highlight the 
dominant themes of a population’s composition as compared with other tools such as 
principal components analysis or neighbor-joining (NJ).  
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RESULTS 
HLA allele frequency  
HLA alleles frequency data are presented for 19 ethnic groups containing a total of 
275,699 subjects from the EM BMDR. A summary of the 20 most common HLA-A, 
HLA-B and HLA-DRB1 alleles and their respective estimated frequencies are presented 
in Supplementary Table S2, S3 and S4. Top 100 alleles frequencies of HLA-A, HLA-B 
and HLA–DRB1 loci are provided in Supplementary Table S1. The most frequent alleles 
for the HLA-A locus were A*01:01, A*02:01 and A*03:02. The most frequent alleles for 
the locus HLA-B were B*35:08, B*49:01 and B*38:01. The most frequent alleles for the 
locus HLA-DRB1 were DRB1*11:04, DRB1*07:01 and DRB1*13:02. HLA-
DRB1*11:04 was observed with a frequency greater than 15% in all populations except 
Yemen and Ethiopia. Locus level deviations from HWE were detected at HLA-A, -B, and 
-DRB1 in 11 of the 19 analyzed populations. The most significant HWE deviation was 
detected at HLA-B among those donors who self-designated themselves as ‘‘Israeli” 
between the homozygous expected and observed counts (5326 expected, 5922 observed, 
p = 4 10 16). This result was expected since the ‘‘Israel” group comprises of donors who 
reported that their parents were born in Israel, however their specific ethnic origin was 
not indicated. Thus, the ‘‘Israel” group is likely to be of mixed ethnicity with parents who 
do not necessarily share the same ethnic origin. Data results of HWE analysis are 
provided in Supplementary Table S5 and S6.  
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Frequent HLA-A, HLA-B and HLA-DRB1 haplotypes  
Supplementary Table S1 illustrates the top 50 ranked A~B~DRB1 haplotypes for all 19 
analyzed populations. The number of haplotypes with a minimum frequency of 10 4 
ranged from 692 to 1579 depending on sub-ethnicity groups. Several haplotypes were 
shared among sub-ethnic populations while others remained private. The haplotype 
A*26:01~B*38:01~DRB1*04:02 was shared among Ashkenazi populations with a 
frequency of 2.3–6.7%. The haplotypes A*33:01~B*14:02~DRB1*01:02 and 
A*30:01~B*13:02- ~DRB1*07:01, common in the US Middle Eastern/North African 
coast population, were common in most sub-ethnicities with frequencies 0.02–5.3%. 
Also, A*02:05~B*50:01~DRB1*07:01, common to most Arab populations, was among 
the top 100 haplotypes in the Ezer Mizion data with frequencies ranging from 0.02% to 
1.29%.  
Classification of populations and haplotypes  
Figure 3 shows the clustering of the Top 100 haplotypes (rows) in the 19 studied sub-
ethnicities, which could be resolved into eight haplotype clusters based on similarities 
across populations (columns). Several inferences can be drawn from the generated 
clusters. As expected, the largest cluster of haplotypes (cluster 4) includes the Ashkenazi 
populations. These populations cluster more tightly together than the non-Ashkenazi 
groups. Other clusters correlate with geographic proximity, such as Iran and Iraq (cluster 
3), Bukhara and Iraq (cluster 2, although Bukhara also contained some private 
haplotypes) and Libya and Tunisia (cluster 5). Other clustering trends were noted. As 
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expected, populations related by immigration patterns form clusters such as Morocco and 
Tunisia, and Ashkenaz, Poland and USSR. In general, HLA haplotypes of most 
Ashkenazi populations cluster together while those of non-Ashkenazi populations are 
more divergent.  
  30 
 
Figure 3. Clustering of the top 100 haplotypes on 19 sub-ethnic populations defined by 
country of origin. 
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DISCUSSION 
 
We described allele and haplotype frequency distribution based on data obtained from 
275,699 hematopoietic stem cell donors, representing 19 different ethnic groups 
contained in the Ezer Mizion Bone Marrow Donor Registry using a maximum likelihood 
model that can resolve genotyping ambiguities. The large sample size of this study 
population validates the findings of previously published haplotype frequencies that 
relied on a smaller sample size with a less stringent HLA-typing resolution14,17–20. 
Addition- ally, we present information regarding unique sub-ethnicities that have not 
previously been reported (Bukhara) or have been reported with limited number of 
subjects (Ethiopia and Druze)19. The sub-ethnic populations of the donors included in this 
study were stratified according to the donors’ self-reporting of their parents’ origin. It 
should be mentioned that the extent to which self- reporting ethnicity or geographic 
ancestry will correspond to genetic ancestry is likely to vary as previously discussed by 
Hollenbach et al.27. This fact is specifically observed in one of our large, but 
undistinguished, self-reported population that is composed of donors who listed 
themselves as ‘‘Israel”. This heterogeneous group likely consists of many mixed sub-
ethnicity donors for whom sub-ethnic assignations cannot be made.  
The cross-sectional nature of our registry permits a detailed view of the 
contemporary Israeli genetic profile. We compared our results to a previously published 
study by the Hadassah registry (HD) in Israel14 which in some ways were similar to our 
data and in other divergent, most likely due to differing sample sizes, resolution level and 
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recruitment strategies. In order to compare both registries we rolled up the EM BMDR 
data to the 2-digit level, which could introduce a source of discrepancy between the 
results. As expected, we have observed that populations of geographic proximity in both 
studies share common haplotype. Examples are (to name a few) Iran, Libya and Israeli in 
the data sets from both registries, Algeria and Morocco in the data set of HD vs. Morocco 
in EM BMDR data set, Argentina in the HD data set vs. Argentina and Uruguay in EM 
BMDR, Germany and Poland in the HD study vs. Poland in EM BMDR donors. Some 
haplotypes emerged as common across different geographic areas, for example, the 
haplotype A*26:01~B*38:01~DRB1*04:02 and A*24:02~B*35:02~DRB1*11:04 are 
common in most Ashkenazi populations while the haplotype 
A*02:05~B*50:01~DRB1*07:01 and A*02:01~B*50:01~DRB1*07:01 were shared in 
Middle Eastern populations in both studies. Some Jewish sub-ethnicities in both the 
Hadassah and EM BMDR registries share some common haplotypes such as: 
A*26~B*38~DRB1*04, A*24~B*35~DRB1*04 and A*24~B*35~DRB1*11. It also 
should be noted that some allele families appear to be shared among most populations 
(e.g. A*02, 24 and 26; B*35, 38 and 50 and DRB1*04, 07 and 11).  
Sub-ethnic and genetic heterogeneity within the Israeli population necessitates a 
population specific unrelated bone marrow donor registry that reflects the commonalities 
and diversities of the overall population. Enhanced representation of both common and 
uncommon alleles increases the likelihood of HLA-matching between Israeli donors and 
Israeli patients (including Jewish patients in the Diaspora) of all sub-ethnicities. The 
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results or our analysis have implications on cross-population matching and can help in 
donor searches and population-based recruitment strategies. Gragert et al. published a 
recent study regarding the likelihood of finding a suitably matched adult donor or cord-
blood unit in the NMDP registry that included projections that account for future registry 
growth28. The development of accurate models for prediction of optimal registry size and 
expansion require the determination of high-resolution HLA haplotype frequencies 
within the target population that includes cross-sectional coverage of sub-ethnicities 
within said population. The haplotype frequencies of the major sub-ethnic groups in the 
EM BMDR presented in this current study are part of a strategic effort to guide 
recruitment goals and expansion of the Ezer Mizion volunteer adult unrelated donor 
registry.  
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SYNOPSIS 
Human Leukocyte Antigen (HLA) haplotype frequencies in a volunteer bone marrow 
donor registry should reflect the frequencies of potential transplant recipients served by 
that registry, a challenge in a country with diverse sub ethnicities of immigrants from 
Eastern and Western cultures, such as Israel. We measured the likelihood of finding 
suitable donors for hypothetical patients drawn from defined sub-ethnicities in the Ezer 
Mizion Bone Marrow Donor Registry (EM BMDR) both from donors within and outside 
the registry now and during the coming decade. On average, bioinformatics modeling 
predicts that, given current donor recruitment trends, 6/6 high-resolution HLA match 
rates for Israelis, which currently stand at 40-55% for most sub-ethnicities, will rise by up 
to 1% per year over the next decade. Sub- ethnicities with historically lower rates of 
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inter-ethnic admixture are less likely to find matches outside of their designated group 
but will also benefit from expansion of the registry, while ethnically-directed drives will 
enhance match rates for currently under- represented sub-ethnicities. Donor searches for 
the same cohort using a large extramural registry was of only slight benefit for most of 
the 19 EM BMDR sub- ethnicities evaluated, confirming that local donor registries that 
reflect the ethnic diversity of the community being served are best equipped to serve the 
needs of their respective communities. Contemporary trends of increasing multi-ethnic 
admixture in Israel may impact the effect of ethnic profiling in assessing future match 
rates for EM BMDR.  
INTRODUCTION 
Hematopoietic Stem Cell Transplantation (HSCT) can be life saving for patients with 
lethal hematologic malignancies and for patients with an ever-expanding list of non- 
malignant hematologic and immunologic disorders
29,30
. As family size in many western 
countries shrinks, patients in need of HSCT must frequently turn to burgeoning bone 
marrow donor registries to seek a matched unrelated donor (MUD). The growth of donor 
registries in countries around the world, their online accessibility, and the improving 
outcome of unrelated HSCT have made this procedure a reality for patients in need31,32. 
The success of unrelated-donor HSCT increases commensurate to the degree of Human 
Leukocyte Antigens (HLA) matching between the donor and the recipient
33–36
. As 
ethnicity affects HLA allele and haplotype frequency and thereby influences the outcome 
of a donor search, a national registry's donor pool should reflect the ethnicities of that 
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nation’s population
27
.  
The Ezer Mizion Bone Marrow Donor Registry (EM BMDR), established in 
1998, is the largest Jewish registry in the world with a roster of more than 800,000 
volunteer adult donors. From its inception and through Dec 2015 the EM BMDR 
provided 950 Hematopoietic Product Cells (HPC) for Israeli patients and 1176 HPCs for 
patients from outside of Israel. Establishing a comprehensive donor pool for the Israeli 
population is an immense challenge. Contemporary Jews comprise an aggregate of 
ethnoreligious communities in Israel and in the Jewish Diaspora. Genetic divergence 
within the greater Jewish population was caused by admixture with indigenous host 
populations on a backbone of Mediterranean ancestry, while cultural and religious forces 
maintained coherence of the Jewish people
13,14,37,38
. Israel is a home to the entire genetic 
spectrum of the Jewish Diaspora as well as to large minorities comprised of non-Jewish 
ethnic groups, leading to substantial ethnic diversity in a country of only 8 million 
individuals. As second-generation Israelis start marrying outside of their ancestral sub-
ethnicities, an additional layer of diversity has been introduced into the HLA landscape in 
Israel, leading to immunogenetic inter- generational differences within the Israeli 
population16.  
Since 2005, the EM BMDR has enrolled stem cell volunteer donors primarily at 
the central induction center of the Israel Defense Forces where military conscripts, at the 
age of 18, are offered enrolment as part of their enlistment process. All Israeli teenagers 
(male and female) of Jewish, Druze, Bedouin or Circassian descent are required to 
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register at this center on or around their 18
th 
birthday. EM BMDR’s recruitment strategy 
has increased the number of young, healthy donors in the registry (37% of registered 
donors are now between 18 and 25 years of age) and has enhanced its HLA diversity to 
reflect the representation of nearly all the sub- ethnicities in the Israeli population 
(according to the Israeli Census report 2014, table 2.8). EM BMDR also conducts 
ethnically focused donor drives within Jewish, Arab and Druze communities in efforts to 
enhance the ethnic representation of specifically targeted groups. Approximately 10% of 
the Israeli adult population is registered in the EM BMDR making it the registry with the 
highest number of HLA-A, -B, -DR stem cell donors per 10,000 inhabitants in the 
world
39
. Despite the size of this donor pool, many Israeli patients in need of a MUD stem 
cell transplant do not find a suitably matched local donor
32
. According to the 2014 
WMDA annual report, 72% of the MUD products required for transplants in Israel were 
procured from Israeli BMDR's, of which 68% were provided by EM BMDR
39
.  
Haplotype frequency estimation using phenotypic population data can permit, 
among other things, an estimate of the size of a theoretical donor pool that will meet the 
needs of a specific patient population
40–42
. In this paper, the likelihood of finding donors 
at different matching stringencies was computed for hypothetical patients from each 
subethnicity, in an effort to show the ability of the current registry (size and sub-ethnic 
representation) to provide stem cell donors for the Israeli population. We also project the 
effects of donor registry growth on the likelihood of successful donor searches within the 
registry.  
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METHODS 
Study Population  
The initial data set included all 754,135 adult volunteer donors registered at EM BMDR 
from its inception through June 2014. All subjects provided informed consent for 
registration at recruitment and provided self-reported information regarding the country 
of origin of each of their parents. Donors were asked to write in the country of parental 
origin and did not choose from a registry-generated list, so as not to limit their answers. 
The study was approved by the Rabin Medical Center Ethics Committee. Study subjects 
were restricted to those individuals who reported the same sub-ethnicity for both parents. 
Multi- or mixed-ethnicity donors were excluded from this analysis. The USA, Argentina, 
and Ashkenazi (donors who did not specify their parents’ geographical origin but 
indicated that they are of Ashkenazi ancestry) sub-ethnic populations are predominantly 
emigrants from Eastern and Western Europe. The SEE (Southeast Europe) sub-ethnic 
population includes Jews from Romania, Bulgaria, Moldova, Greece, Yugoslavia, 
Albania, Serbia, Transylvania, and Cyprus. The USSR sub-ethnic population includes 
Jews from Russia, Ukraine, Belarus, Lithuania, Latvia and Eastern Europe. Donors who 
listed "Israel" as their sub-ethnicity reflect a diverse group whose parents do not 
necessarily share the same ethnic origin; these donors did not indicate their parents' 
ethnicity but their parents’ country of birth. For the purpose of this study, all EM BMDR 
donors who met the above criteria were used as potential patients seeking an unrelated 
stem cell donor.  
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Modeling and Definitions  
Match rate projection tools were developed by the National Marrow Donor Program 
(NMDP)/Be The Match® Bioinformatics Research Department and were previously 
applied to the Be The Match (USA) registry
43
. For the purpose of this study, HLA- 
matching models were based on donor–recipient three-locus (HLA-A, -B, and - DRB1) 
high-resolution haplotype frequencies of the EM BMDR sub-ethnicities
28
. Matching at all 
three loci is termed a 6/6 HLA match. A ≥5/6 allele match includes matches of all six 
alleles of the donor-recipient pairs or allows for a single mismatched allele ("5/6 or 
better"). In addition, we analyzed the probability of identifying donors from “within” and 
"outside" of the patient’s sub ethnic group accounting for current donor availability rates. 
The match rate for searches outside the donor's ethnic group is calculated by subtracting 
the "within" match rate from the "cumulative" match rate using the entire registry, it 
therefore represents the matches that could not be found from first searching within the 
given population.  
Availability of Donors  
Many factors affect the availability of registered volunteer donors
44
. Availability rates of 
potentially HLA-matched donors are given for the three stages of the MUD search 
process: Confirmatory Typing (CT), donor validation, and medical clearance. At the CT 
stage, a blood sample is obtained from identified potentially matching volunteers to 
confirm HLA typing. Preliminary serological testing for infectious agents is also 
performed. Donor unavailability at this stage may result from failure to locate the donor, 
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donor health-related issues, or scheduling conflicts. At the donor validation stage, the 
initially inferred HLA typing at preliminary search is compared with the results of CT; 
discrepancies might invalidate the donor. Lastly, MUDs receive detailed information 
about the donation process and their medical eligibility is determined; at this stage, a 
donor may decline to continue or may be deemed medically unfit to donate stem cells. 
Donor availability rates were similar among the various sub-ethnic populations in the EM 
BMDR registry, and the cumulative availability factor was calculated by multiplying the 
percentages of availability at the three respective stages, treating each stage as 
provisional for each subsequent event (Table 4). Match rates were adjusted for 
availability in our model by multiplying the number of donors in each analyzed 
population by this cumulative availability factor
43
.  
Table 4. Adult-Donor Availability in 2015 requested from EM BMDR 
†Confirmatory 
Typing Available 
(%) 
‡ Typing not 
Discrepant (%) 
§ Workup 
Available 
(%) 
Available 
Overall (%) 
80 99.4 94 75 
 
† Shown are data for donors who can be contacted and who have a DNA sample collected for confirmatory HLA typing. 
‡ Shown are data for donors whose confirmatory HLA typing was consistent with HLA typing performed at recruitment. 
§ Shown are data for donors who were cleared as healthy by means of a medical examination and who agreed at this 
stage to proceed toward donation. 
Statistical Analysis  
We included 275,699 donors of the initial dataset from 67 sub-ethnicities who had been 
genotyped by DNA methods at HLA-A, -B and -DRB1 loci, with an average sample size 
of 5,200 per sub-ethnicity [2 – 69,717]. Due to progressive changes in HLA genotyping 
technology, the registry data contains donors at varying levels of resolution. Only sub-
ethnicities with a minimum of 200 high-resolution (first two nomenclature fields) typed 
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samples at HLA-A, -B and -DRB1 were included in this study; nineteen sub-ethnic 
populations met this selection criterion
44
. We used the Expectation Maximization (EM) 
algorithm designed to handle mixed resolution data and to resolve both allelic and phase 
ambiguity
21–23,45
, in order to estimate HLA A~B~DRB1 haplotype frequencies for each 
population
28
. The haplotype frequencies and effective donor registry sizes for each 
population were put into a matching model46–48
 
and deviations from Hardy–Weinberg 
equilibrium (HWE) were 7 assessed at the allele-family level
28
. We used the model to 
calculate the population- specific HLA match rates for the given registry size and match 
definitions. Match rates were defined as the likelihood at which each individual from a 
given sub-ethnic population would find an allele matched adult donor by searching the 
same sub- ethnic population, other sub-ethnic populations, or the entire EM BMDR donor 
list. Adult donor match rates were modeled for each of the sub-ethnic populations over a 
range of potential registry sizes that predicted growth proportional to the initially reported 
sub-ethnic population size. A projected annual registry growth rate of 6% for the next 10 
years was selected for this analysis based on annual growth rates of the registry during 
the previous decade. We assume a proportional expansion of each sub-ethnicity from its 
current representation based on this growth rate and did not account for future ethnically-
driven donor recruitment drives. 
Marginal Benefit Analysis  
We modeled the allele-level 6/6 and ≥5/6 adult donor match rates for patients utilizing 
the donor pools of both EM BMDR and Be the Match registries, in order to assess the 
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effect conferred by the existence of EM BMDR on finding donors for potential patients 
drawn from the study populations enumerated above. We used previously published 
A~B~DRB1 haplotype frequencies for 21 race groups for modeling the Be the Match 
registry. The number of donors in each race group ranged from 1,469 for Alaskan Native 
to 2,899,081 for European. A donor availability factor could not be assessed for some 
ethnicities due to the low number of transplants performed for minority patients in Be the 
Match registry. We accounted for donor availability in the models by multiplying the 
number of donors in each of the 21 populations in Be the Match registry by the donor 
availability of their corresponding broad race group. We calculated match rates attained 
from searching 8 only the Be the Match registry for all individuals from each of the 19 
sub-ethnic populations analyzed from the EM BMDR at the 6/6 and ≥5/6 level, and 
termed this "marginal benefit"
24
.  
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Figure 4. 6/6 and 5/6 stacked match rates considering 75% overall donor's availability. For each 
population, the shown match rates describe the rate at which patients from this population would 
find an allele-matched donor by searching the entire Ezer Mizion registry. 
 
RESULTS 
Adult Donor Match Rates  
Figure 4 shows the 5/6 and 6/6 overall match rates for the sub-ethnic populations 
analyzed in the EM BMDR considering a 75% cumulative donor availability rate. Most 
patients will have a 6/6 or ≥5/6 HLA MUD available from within the registry. For the 
majority of sub-ethnic populations, 6/6 match rates are 40-55%, with the exception of the 
Tunisia (36%) Kavkaz (33%), Druze (33%) Yemeni (31%), Arab (17%) and Ethiopian 
(12%) populations. When allowing for a single HLA-allele mismatched donor, potential 
transplant candidates from all sub-ethnic populations have a match rate ≥ 80% with the 
exception of Arab (77%) and Ethiopian (66%) sub- ethnic populations. Although 6/6 and 
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≥5/6 loci HLA-match rates are greatest within most sub-ethnic population (with the 
exception of Argentina, Ashkenaz, SEE and USA – relatively small and very 
heterogenous groups)(Table 6), exploiting potential donors from other ethnic groups may 
enhance the chances of finding suitably matched donors (Supplementary Table S7). 
Individuals belonging to sub-ethnic populations with high levels of genetic admixture, 
(Ashkenazi and European [Argentina, Poland, USA], have 21-31% 6/6 matched rate with 
donors identified outside their ethnic group. By contrast, potential patients from sub-
ethnicities with lower levels of genetic admixture and unique allele representations
44
, 
rarely find extramural 6/6 matched rate donors (Bukhara 7.6%; Druze 7.7%; Yemen 
2.3%; Ethiopia 0.8%). It should be noted that patients belong to sub-ethnicities with large 
sample size (Israel, Morocco, USSR) also present low rate of extramural matching since 
they have higher chance to find matched donors from within their own population.  
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Table 5. 6/6 and ≥5/6 adult donor match rates and marginal benefit for EM BMDR patients 
utilizing the donor pools of both EM BMDR and Be the Match® 
Ethnicity Cumulative 6/6 
Marginal Benefit 
6/6 
Cumulative 
≥5/6 
Marginal  
Benefit 
≥5/6 
ARAB 0.394 0.225 0.945 0.171 
ARGENTINAa 0.542 0.071 0.954 0.050 
ASHKENAZ 0.499 0.091 0.948 0.053 
BUKHARA 0.487 0.056 0.937 0.042 
DRUZE 0.389 0.056 0.950 0.057 
ETHIOPIA 0.169 0.046 0.822 0.155 
GEORGIA 0.469 0.065 0.946 0.038 
IRAN 0.544 0.082 0.978 0.039 
IRAQ 0.504 0.100 0.965 0.045 
ISRAEL 0.599 0.069 0.983 0.024 
KAVKAZ 0.479 0.140 0.954 0.079 
LIBYA 0.502 0.070 0.954 0.048 
MAROCCO 0.560 0.084 0.975 0.036 
POLAND 0.654 0.130 0.987 0.039 
SEE b 0.629 0.074 0.977 0.029 
TUNISIA 0.460 0.099 0.948 0.056 
USA 0.643 0.085 0.977 0.030 
USSR c 0.568 0.143 0.975 0.052 
YEMEN 0.343 0.029 0.878 0.051 
a Argentina and USA population are derived from emigrants of European Jews 
b SEE include Romania, Bulgaria, Moldova, Greece, Yugoslavia, Albania, Serbia, Transylvania and Cyprus 
c USSR include Russia, Ukraine, Belarus, Lithuania, Latvia and East Europe 
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Figure 5. Adult donor 6/6 projected match rates (based on current donor availability) for each 
sub-ethnic population were modulated for 2014 through 2024. Calculations were based on 
anticipated growth of 6% cumulatively each year.  
Donor Registry Growth  
We projected expansion of the registry roster from 2016 to 2026. Projected match rates 
were calculated based on anticipated growth of 6% cumulatively each year and 75% 
donor availability. We forecast that aggregate 6/6 (Figure 5) match rates will improve by 
0.5 to 1% per population per year through 2026. We compared changes in match rates for 
specific sub-ethnicities and found that Druze (9.8%) and Georgia (9.3%) populations 
experienced the most rapid growth in this metric. As expected, populations who already 
have high match rates using the current registry donor roster and who have high levels of 
genetic admixture, (Ashkenazi and European) will reap lower benefits from projected 
registry growth (6-7.5%). We also modeled 6/6 and ≥5/6 HLA-allele donor match rates 
given a doubling the total registry roster from 750,000 to 1,500,000 donors (Figure S8 in 
supplementary material). “Six of 6” allele aggregate match rates rose from 52% to 62% 
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for the entire registry cohort. The increase of donor-recipient matches by sub-ethnicity 
ranged from 6.8% – 12.3%, with highest levels among the Druze community. The 
aggregate increase in match rate for ≥5/6 donor-recipient pairs with doubling of the 
registry size was a more modest 2.5% (from 94.2% to 96.7%), with Ethiopian, Arab and 
Yemeni match rates rising 7.9%, 5.3% and 4%; all other groups showed only nominal 
increases.  
Marginal Benefit Analysis with Be the Match Donor Registry  
Allele-level 6/6 match rates for patients searching both the Ezer Mizion and Be the Match 
registries ranged from 16.9% to 65.4% for Ethiopia and Poland sub- ethnicities, 
respectively (Table 6). Cumulative 6/6 match rates in Table 5 represent the sum of the 
cumulative 6/6 match rates from Table 6 (using the EM BMDR pool alone) plus the 
marginal benefit added by searching the Be The Match pool of donors. For most potential 
patients searching both registries, the likelihood of finding a 6/6 matched donor exceeds 
46%; exceptions include Ethiopian, Druze, Yemeni and Arab individuals. On average, 
potential patients from the Ethiopia, Druze, Yemen, and Arab sub-ethnic populations are 
22% less likely to find a 6/6 matched donor in both registries than individuals from other 
populations. When allowing for a single HLA-allele mismatch ("5/6 or better"), most 
sub-ethnic populations have match rates exceeding 94%, with the exception of the 
Yemen and Ethiopia sub-ethnic populations.  
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Table 6. Probability of identifying adult donors from within and outside of the patient’s sub 
ethnic group incorporating consideration of donor availability.  
Ethnicity Cumulative 6/6 
Within 
Population 
6/6 
Outside 
Population 
6/6 
Cumulative 
≥5/6 
Within 
Population 
≥5/6 
Outside 
Population 
≥5/6 
ARAB 0.170 0.069 0.101 0.774 0.543 0.231 
ARGENTINAa 0.471 0.163 0.309 0.904 0.594 0.310 
ASHKENAZ 0.407 0.164 0.243 0.895 0.595 0.301 
BUKHARA 0.431 0.355 0.076 0.895 0.751 0.144 
DRUZE 0.333 0.256 0.077 0.894 0.762 0.132 
ETHIOPIA 0.122 0.114 0.008 0.667 0.565 0.101 
GEORGIA 0.404 0.314 0.091 0.908 0.768 0.141 
IRAN 0.463 0.381 0.082 0.940 0.834 0.105 
IRAQ 0.404 0.318 0.086 0.919 0.820 0.100 
ISRAEL 0.530 0.446 0.084 0.959 0.918 0.041 
KAVKAZ 0.338 0.217 0.122 0.875 0.610 0.265 
LIBYA 0.432 0.280 0.152 0.907 0.720 0.187 
MAROCCO 0.477 0.420 0.057 0.939 0.884 0.055 
POLAND 0.525 0.309 0.216 0.948 0.797 0.151 
SEEb 0.555 0.275 0.281 0.948 0.766 0.182 
TUNISIA 0.361 0.205 0.155 0.892 0.716 0.176 
USA 0.558 0.239 0.319 0.947 0.708 0.239 
USSRc 0.424 0.327 0.097 0.923 0.852 0.072 
YEMEN 0.314 0.291 0.023 0.827 0.753 0.074 
a Argentina and USA population are derived from emigrants of European Jews 
b SEE include Romania, Bulgaria, Moldova, Greece, Yugoslavia, Albania, Serbia, Transylvania and Cyprus 
c USSR include Russia, Ukraine, Belarus, Lithuania, Latvia and East Europe 
 
The average marginal benefit achieved for potential patients from EM BMDR by 
searching the Be the Match donor pool for a 6/6 matched donor was 9%, but varied by 
sub-ethnicity. Specifically, marginal benefits of this extramural search ranged from 3% 
for Yemeni recipients to 22% for Arab patients. The likelihood of finding a 6/6 matched 
donor for potential EM BMDR recipients only in the Be the Match® registry is < 10% 
for most patients, except for Poland (13%), Kavkaz (14%), USSR (14%), and Arab 
(22%) sub-ethnic populations. Comparative figure for equivalent match rates in EM 
BMDR are 52%, 33%, 42%, and 17% for these same populations, respectively. The Arab 
population was the only population more likely to find a 6/6 matched donor in the Be the 
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Match registry than in EM BMDR. The likelihood of finding a ≥5/6 matched donor only 
in the Be the Match registry for EM BMDR potential patients was less than 8%, except 
for the Ethiopia (15%) and Arab (17%) sub-ethnic populations.  
DISCUSSION  
Analysis of a target population’s HLA profile is integral to strategic planning for the 
establishment and expansion of stem cell donor registries that will provide an optimal 
representation of the population that they are meant to serve. We used HLA A~B~DRB1 
haplotype frequencies from 19 sub-ethnic populations of adult volunteer donors from 
within our registry to estimate match rates for hypothetical domestic patients given the 
current size of the EM BMDR. We assessed the effects that non- directed short-term 
growth of the registry (expansion of the donor pool without ethnicity-directed donor 
drives) would have on matching frequencies for Israelis patients of these sub-ethnicities 
who seek a stem cell donor. Using a population- based genetic model
43 
with selection 
criteria that predict the likelihood of finding 6/6 or ≥5/6 HLA-matched donor and 
accounting for our current rate of donor availability, we charted the effect that enlarging 
the registry would have on HLA-match rates over the next decade. Each donor whose 
parents were of the same sub-ethnicity was used as a potential stem cell transplant 
recipient for the purpose of this analysis.  
Our results show that 40-55% of potential transplant recipients from most of the 
sub- ethnic populations studied will find a 6/6 HLA allele-matched donor within the EM 
BMDR registry. Searches performed at lower stringency (≥5/6 matching stringency), 
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resulted in match rates of ≥ 80% for patients from most of the sub-ethnic populations. 
Some sub-ethnic populations continue to have lower match rates within EM BMDR 
because of lower representation in the registry (Arab and Druze donors) or due to distinct 
HLA allele frequencies, likely the result of limited admixture with the greater Jewish 
Diaspora (Ethiopian, Kavkazi, and Yemen). Given projected donor enrollment rates, we 
anticipate adding approximately 500,000 donors to EM BMDR by 2026. We predict an 
aggregate improvement in 6/6 match rates of 0.5% to 1% per population per year during 
this period (Figure 5). Although directed donor recruitment will alter this dynamic for 
currently under-represented groups, all other population in our registry will benefit from 
ongoing recruitment efforts. More importantly, our model does not account for future 
shifts in the immigration patterns or for multi-ethnic admixtures in Israeli society over the 
coming decade. Assuming that the discrete sub-ethnicities on whom we have reported 
maintain their unique HLA haplotype frequencies, we forecast improved match rates for 
some currently under-represented sub-ethnicities that are moderately higher than the 
effects of registry growth on the EM BMDR population as a whole. A registry's mandate 
is to expeditiously identify the best available donor
49
. Our findings are consistent with 
those reported by Gragert et al.,43 
 
and point to the futility of delaying transplant for a 
patient who does not find a donor in the hope that one will be identified in the near 
future.  
The EM BMDR is predominantly supported by charitable and personal 
contributions, and donor recruitment is a costly process. As the stewards of philanthropic 
funds, we must allocate the resources of the registry responsibly. As such, we assessed 
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the need for registry expansion by looking at the match rates from extra-mural donors, 
taken in this case from the Be the Match registry. Results of this analysis showed that 
existence of the EM BMDR adds substantial benefit for Israelis who would require an 
unrelated stem cell transplant. Of interest, the Arab population in our country gained 
most from searching the extramural registry. We project that directed donor drives in this 
community will be required to improve local match rates for Arab patients. Our model 
calculated match rates using 6 HLA alleles typed at high resolution. Searches at higher 
levels of stringency, such as inclusion of typing at HLA-C, will likely result in reduced 
match rates
50
. Additionally, our models assume HWE and were solely conducted using 
donors who listed both of their parents as belonging to the same sub-ethnicity. Recent 
data suggests that contemporary Israel is undergoing profound ethnic changes
15 
; East is 
meeting West and they are bearing children. As such, models assuming HWE may not be 
valid. The results of sub-ethnic admixture in contemporary Israeli society are already 
apparent in the lower numbers of fully HLA matched unrelated donors actually found for 
children as compared with adult transplant recipients in Israel
16
. Exploring haplotype 
frequencies and match rates for the growing multi-ethnic population base in the EM 
BMDR will set the foundation for elaborating strategies for recruitment and expansion of 
the registry, and will highlight the value added to the international community through 
the contribution of multi- ethnic donors in an increasingly globalized community.  
This study utilized donor self-reporting of sub-ethnicity, which has been shown to 
be less than completely reliable27. Additionally, a large group of donors was excluded 
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from analysis due to absence of data regarding parental ethnicity or due to multi- ethnic 
lineages. As noted above, changes in reproductive patterns in contemporary Israel will 
likely change the sub-ethnic landscape in the coming decades. As sub- ethnic admixture 
will likely result in changing representation of HLA-allele frequencies in our populations, 
we have begun to collect data regarding grandparental sub-ethnicities in an effort to guide 
future analyses. Our data-driven approach will help plan the expansion and recruitment 
policies of the EM BMDR and aid Israeli and non-Israeli patients worldwide in their 
search for a stem cell donor. 
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APPENDIX	A	
 
Locus	 Feature	 Rank	 Number	Matched	 Percent	Matched	
HLA-A	 EXON	 1	 383	 50.86%	
HLA-A	 EXON	 2	 2667	 73.19%	
HLA-A	 EXON	 3	 1495	 41.03%	
HLA-A	 EXON	 4	 1348	 97.89%	
HLA-A	 EXON	 5	 383	 52.04%	
HLA-A	 EXON	 6	 383	 76.14%	
HLA-A	 EXON	 7	 383	 76.14%	
HLA-A	 EXON	 8	 383	 77.53%	
HLA-A	 FIVE_PRIME_UTR	 1	 88	 26.83%	
HLA-A	 INTRON	 1	 383	 100.00%	
HLA-A	 INTRON	 2	 383	 100.00%	
HLA-A	 INTRON	 3	 383	 100.00%	
HLA-A	 INTRON	 4	 383	 100.00%	
HLA-A	 INTRON	 5	 383	 100.00%	
HLA-A	 INTRON	 6	 383	 100.00%	
HLA-A	 INTRON	 7	 383	 100.00%	
HLA-A	 THREE_PRIME_UTR	 8	 353	 100.00%	
HLA-B	 EXON	 1	 416	 44.30%	
HLA-B	 EXON	 2	 3175	 71.28%	
HLA-B	 EXON	 3	 1730	 38.84%	
HLA-B	 EXON	 4	 1602	 99.63%	
HLA-B	 EXON	 5	 416	 49.52%	
HLA-B	 EXON	 6	 416	 77.18%	
HLA-B	 EXON	 7	 416	 78.64%	
HLA-B	 FIVE_PRIME_UTR	 1	 6	 1.78%	
HLA-B	 INTRON	 1	 416	 100.00%	
HLA-B	 INTRON	 2	 416	 100.00%	
HLA-B	 INTRON	 3	 416	 100.00%	
HLA-B	 INTRON	 4	 415	 99.76%	
HLA-B	 INTRON	 5	 416	 100.00%	
HLA-B	 INTRON	 6	 416	 100.00%	
HLA-C	 EXON	 1	 590	 71.78%	
HLA-C	 EXON	 2	 3267	 99.30%	
HLA-C	 EXON	 3	 651	 19.79%	
HLA-C	 EXON	 4	 1171	 96.94%	
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HLA-C	 EXON	 5	 590	 72.66%	
HLA-C	 EXON	 6	 590	 74.87%	
HLA-C	 EXON	 7	 590	 84.17%	
HLA-C	 EXON	 8	 590	 91.90%	
HLA-C	 FIVE_PRIME_UTR	 1	 13	 2.37%	
HLA-C	 INTRON	 1	 590	 100.00%	
HLA-C	 INTRON	 2	 590	 100.00%	
HLA-C	 INTRON	 3	 590	 100.00%	
HLA-C	 INTRON	 4	 590	 100.00%	
HLA-C	 INTRON	 5	 590	 100.00%	
HLA-C	 INTRON	 6	 590	 100.00%	
HLA-C	 INTRON	 7	 590	 100.00%	
HLA-C	 THREE_PRIME_UTR	 8	 556	 100.00%	
Table 7. The number of times the expected accession number for a given feature and rank 
matches the observed. 
 
 
Locus	 Feature	 Rank	 Count	
HLA-A	 EXON	 2	 137	
HLA-A	 EXON	 3	 222	
HLA-A	 EXON	 4	 5	
HLA-A	 EXON	 5	 14	
HLA-B	 EXON	 2	 163	
HLA-B	 EXON	 3	 285	
HLA-B	 EXON	 5	 2	
HLA-C	 EXON	 3	 270	
HLA-C	 EXON	 4	 3	
Table 8. The number of times the expected and observed sequences for a given feature and rank 
are off by three base pairs at the beginning or end of the sequence. 
 
 
